Proceedings of MATSUS23 & Sustainable Technology Forum València (STECH23) (MATSUS23)
DOI: https://doi.org/10.29363/nanoge.matsus.2023.191
Publication date: 22nd December 2022
The pulmonary administration of nanomedicines such as viral vaccines is a promising delivery route because it is direct, noninvasive, and it can be used for both systemic delivery and lung targeting. However, the same mechanisms that protect us from pathogens entering via the inhalation route lead to the rapid elimination or degradation of nanomedicines. Most nanomedicines designed for pulmonary administration do not reach clinical practice and this is reflected in the low number of newly approved inhalation drugs.[1] This reality contrasts with the increase in lung diseases due to global ageing and new infectious diseases.[2] Since one of the advantages of pulmonary administration is the direct targeting of the lung, the challenges of improving this route of administration are worthy of being addressed towards overcoming unmet clinical needs. In this context, we will demonstrate that it will be key to study and understand the nano-bio interaction with lung barriers to design better drug nanovectors. To this end, we will give examples of how multifunctional nanoparticles capable of encapsulating drugs and being labeled with contrast agents to perform multiscale studies will be an essential tool to characterize these interactions.[3] We will provide examples of how different coating agents determine lung retention time, clearance by alveolar macrophages, penetration into the lung, etc. Finally, we will show how this may impact the therapeutic efficiency of some of these nanomedicines.
SCR is supported by the Ministerio de Ciencia e Innovación (PID2019-106139RA-100 and RYC2020-030241-I). JRC is funded by MCIN/AEI/10.13039/5011000011033, "ERDF A way of making Europe" (PID2021-123238OB-I00), La Caixa Foundation (HR20-00075) and from the Spanish Fundación contra la Hipertensión Pulmonar.